Scientists say the presence of antibodies may not guarantee protection from Kovid-19

Scientists say the presence of antibodies may not guarantee protection from Kovid-19

Let’s Start this Interesting Article Shared on

NEW DELHI: The presence of antibodies indicates previous exposure to the SARS-CoV-2 virus, but may not always translate into protection against the disease, scientists say, and how long such antibodies last. As concerns over India’s Kovid-19 spike mount, “the country added 90,062 cases on Monday, surpassing the 42 lakh mark” scientists are grappling with the decisive issue of antibodies and trying to understand How they affect the progression of the disease. .
Read our Coronavirus live blog for all the latest news and updates.
But the jury is still out with many studies and hypotheses but no consensus yet. The scientists said that the only thing that can be said with any degree of uncertainty is that the antibody is an indication that the person is already infected with the novel coronavirus.
Coronavirus outbreak: full coverage
Immunologist Satyajit Rath said that he would like to see and white? Where there is evidence.
The scientist at the National Institute of Immunology (NII) in New Delhi said that the presence of antibodies in itself does not tell us anything about the progression of the disease in individuals.
More on Kovid-19

There are also neutralizing antibodies (nAbs) and imsimple ‘antibodies. Although NABS manufactured against novel coronaviruses can block its entry into the host cell, other antibodies are also generated against many parts of the virus, added Vinita Bal from the Indian Institute of Science, Education and Research (IISER), Pune .
Thesimple ‘antibody is an indication of the host’s response to viral presence but is not useful to prevent further spread of the virus, Baal told PTI.
 € œSimple presence of antibodies is a clear indication of previous exposure to SARS-CoV2, but does not necessarily guarantee protection from disease in the event of neutralizing antibodies? The immunologist said.
The duration of nAbs in sufficient concentrations and the next exposure to long-term is the most likely indicator of a person’s protection from the disease ie Kovid-19? He explained.
Bal also stated that from a public health point of view there is no consensus to ensure levels of nAbs are ‘protective’ or that plasma therapy may be useful.
Different sero-survey trials have been conducted in India in the last few months to indicate the actual number of infected cases in the country. A sero-survey involves testing the blood serum of a group of individuals for the presence of antibodies against that infection to find out who has been infected in the past and is now cured. Surveys conducted in the metros suggest that the Kovid-19 cases are much higher than actually reported.
According to Rath, one of the many problems in looking for easy patterns in serological evidence is that not everyone is using the same antibody tests.
In fact, not all antibody tests in the market are against the same viral protein target, and some investigators use only one target, others use more. And it is possible that the tests differ in their sensitivity,? Rath told PTI.
The scientist also said that most surveys are reporting people only as ‘positive’ or ‘negative’, and not analyzing the antibody levels present in the blood. The limited evidence available so far suggests that these antibody tests appear to be correlated with theprotective? Also antibody levels. However, there is not much that can be said about the risk to individual people of their reinforcement or their level of protection. Various studies, including one recently published in the Journal of Clinical Microbiology, have also suggested that those infected with Kovid-19 develop antibodies that can protect them from regeneration. However, recently reported reinfection cases from around the world have fueled that optimism. Throwing more light on the issue, Bal said that the re-creation of a person does not mean that he becomes ill with Kovid-19.
Even the presence of sufficient NABs capable of neutralizing a variant virus will not prevent infection, Baal said. However, in all probability, such a person with ‘protective immunity’ is likely to handle subsequent infections – including those currently reported as reinforcements – better and with less morbidity than otherwise. â € œReinfections should not be equated with the disease due to repetition of similar or related viruses? He said that a recent case of revision in person in Hong Kong was discovered due to screening tests rather than symptoms.
While it is not clearly known whether people who produce antibodies against SARS-CoV-2 are protected from re-infection, scientists do not even know how long those antibodies persist.
A study published on September 1 in the NEJM Journal found that antibodies against the new coronavirus remain in the body for up to four months after infection, quickly disappearing earlier evidence suggesting these important immune molecules.
The study measured SARS-CoV-2 antibody levels in the blood of about 30,000 people, including more than 1,200 people who tested positive for the virus and recovered from Kovid-19 in Iceland.
90 percent of the people recovered had antibodies against the virus.
Based on an Iceland study, we know that antibodies produced by natural infection can last up to four months, perhaps longer? Baal said.
At the moment, there is no idea as to what percentage of those previously exposed will be susceptible to disease-mediated immune enhancement (ADE) when re-exposed to a variant of SARS-CoV-2 or related viruses. It is done, he said.
ADE is a phenomenon in which the binding of a virus to an antibody increases its penetration into host cells after its replication. This is a general concern for the development of vaccines and antibody therapy.
Rath said Iceland’s study appears to be quite intensive in many respects, and shows antibody persistence for about four months. “Is this going to happen everywhere?” I have no presumption to tell that I am afraid no. As far as disease progression in communities, antibody evidence tells us how much the virus has spread and in which places – communities, although we get more detailed and repeated Need to sero- survey to be able to know anything more than ‘it is quite spread, or perhaps a lot’? The chariot said.


Leave a Reply

Your email address will not be published. Required fields are marked *